Research and Markets: Fibromyalgia Therapeutics - Global Strategic Business Report

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/dpmcng/fibromyalgia) has announced the addition of the "Fibromyalgia Therapeutics - Global Strategic Business Report" report to their offering.

“Fibromyalgia Therapeutics - Global Strategic Business Report”

This report analyzes the worldwide markets for Fibromyalgia Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

The report profiles 26 companies including many key and niche players such as:

- Boehringer Ingelheim GmbH

- Chelsea Therapeutics Inc.

- Claire Ellen Products Inc.

- Eli Lilly and Company

- Forest Laboratories Inc.

- Impax Laboratories Inc.

- Meda AB

- Pfizer Inc.

- Pierre Fabre Médicament

- Synthetic Biologics Inc.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Total Companies Profiled: 26 (including Divisions/Subsidiaries - 31)

The United States (18)

Canada (1)

Japan (6)

Europe (5)

- France (1)

- Germany (1)

- Rest of Europe (3)

Asia-Pacific (Excluding Japan) (1)

For more information visit http://www.researchandmarkets.com/research/dpmcng/fibromyalgia